Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Insights
Blogs
Sharing perspectives leads to greater understanding and fuels innovation
Check out our latest blog posts:
|
October 25, 2023 · Public Policy & Regulatory Affairs Team
Brief updates in California workers’ comp PTSD presumption law amended and several other bill vetoed; Michigan legislation would significantly overhaul auto no-fault medical fee schedule law; Massachusetts to hold meetings on opioids; and Tennessee clarifies medical fee schedule updates. Read more... |
|
October 12, 2023 · Clinical Team
The 3Q 2023 Brand-Generic Pipeline update Read more... |
|
October 11, 2023 · Medicare Insights Team
On October 10, 2023, CMS finalized its Civil Monetary Penalty (CMP) rule for imposing penalties against Responsible Reporting Entities (RREs), which includes Group Health Plans (GHPs) and Non-Group Health Plans (NGHPs). Read more... |
|
|
October 04, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include Colorado furthering limits on physician dispensing in work comp, California work comp bill requiring in-state licensure for UR physicians on hold, Arizona Fee Schedule features new DMEPOS requirements, Tennessee activates Certified Physician Program and New York PTSD bill keeps moving. Read more... |
|
|
September 20, 2023 · Clinical Team
Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more... |
|
|
September 15, 2023 · Clinical Team
According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more... |
|
|
September 13, 2023 · Public Policy & Regulatory Affairs Team
Read more... |
|
|
September 01, 2023 · Clinical Team
Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more... |
Page 3 of 19
